Icariside II

Icariside II is a bioactive flavonoid glycoside derived from Epimedium species (horny goat weed) and a primary metabolite of icariin following intestinal hydrolysis. It exerts its effects primarily through modulation of VEGF signaling, MMP2 inhibition, and apoptotic pathway activation, making it a subject of active preclinical oncology and anti-inflammatory research.

Origin & History

Icariside II is a prenylated flavonoid glycoside naturally occurring in Epimedium species (horny goat weed), appearing as yellow needle-shaped crystals. It is produced as the main metabolite of icariin through enzymatic hydrolysis in the body, with a molecular formula of C27H30O10.

Historical & Cultural Context

While Icariside II itself has no documented traditional use, it derives from Herba Epimedii (Epimedium species), which has been used in Traditional Chinese Medicine. Specific historical applications for the isolated compound are not detailed in available sources.

Health Benefits

• May inhibit cancer cell growth through VEGF and MMP2 pathway modulation (preliminary evidence from cell studies only)
• Potential anti-inflammatory effects demonstrated in preclinical models (no human data available)
• May induce apoptosis in tumor cells via multiple molecular targets (limited to in vitro studies)
• Possible autophagy regulation through mTOR and AMPK pathways (animal studies only)
• Potential antineoplastic properties targeting aldolase A and enolase 1 (preclinical evidence only)

How It Works

Icariside II suppresses tumor angiogenesis by downregulating vascular endothelial growth factor (VEGF) expression and inhibiting matrix metalloproteinase-2 (MMP2) activity, which reduces cancer cell migration and invasion. It promotes apoptosis by activating caspase-3 and caspase-9 cascades while modulating the Bcl-2/Bax ratio in favor of pro-apoptotic signaling. Additionally, it inhibits NF-κB pathway activation, reducing downstream production of pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6 in preclinical inflammatory models.

Scientific Research

No human clinical trials, RCTs, or meta-analyses for Icariside II have been conducted. All available evidence is limited to preclinical cell culture and animal studies demonstrating anticancer effects through various molecular pathways.

Clinical Summary

Research on Icariside II remains almost entirely at the in vitro and rodent model stage, with no completed randomized controlled trials in humans as of 2024. Cell-based studies have demonstrated dose-dependent inhibition of proliferation in prostate, breast, and hepatocellular carcinoma cell lines at concentrations ranging from 10 to 80 μM. Animal studies in murine models of inflammation showed statistically significant reductions in paw edema and inflammatory biomarkers, though translational relevance to human dosing is unestablished. The overall evidence base is preliminary, and no clinical efficacy or safety conclusions can be drawn for human supplementation.

Nutritional Profile

Icariside II is a flavonoid glycoside (specifically a prenylflavonoid) derived from Epimedium species (Horny Goat Weed), functioning as a bioactive compound rather than a nutritional macronutrient — it contains no meaningful protein, fat, fiber, or caloric value in supplemental context. It is a metabolite of Icariin, formed via enzymatic hydrolysis removing one sugar moiety, yielding higher bioavailability than its parent compound Icariin. Molecular weight: approximately 676.7 g/mol. Typical concentrations in standardized Epimedium extracts range from 0.1–2% by weight, with isolated supplemental forms appearing in research doses of 10–100 mg in preclinical studies. Bioavailability is notably superior to Icariin due to reduced glycosylation; oral absorption is facilitated by intestinal glycosidases, though precise human bioavailability percentages remain unestablished. It demonstrates lipophilic characteristics that may enhance membrane permeability. No significant vitamin, mineral, or fiber content is associated with the isolated compound.

Preparation & Dosage

No clinically studied dosage ranges are available due to absence of human trials. Preclinical formulations include phospholipid complexes and TPGS combinations, but human doses have not been established. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Icariside II pairs meaningfully with Quercetin, as both modulate VEGF signaling and share complementary inhibition of PI3K/Akt/mTOR pathways — Quercetin (500–1000 mg standardized) may amplify the autophagy-regulating effects Icariside II exerts through AMPK activation. Berberine represents a strong mechanistic partner, since Berberine (500 mg) independently activates AMPK while also suppressing MMP2 expression, creating additive downregulation of the same invasion-related pathways targeted by Icariside II in preclinical tumor models. Curcumin (500 mg with piperine for absorption) complements Icariside II's anti-inflammatory preclinical profile through parallel NF-κB suppression and shared modulation of pro-inflammatory cytokines (TNF-α, IL-6), while piperine itself may incidentally improve Icariside II's own intestinal absorption by inhibiting P-glycoprotein efflux.

Safety & Interactions

Human safety data for isolated Icariside II supplementation is essentially absent, as most toxicology data comes from its parent compound icariin and whole Epimedium extracts. Epimedium-based products have been associated with hepatotoxicity in case reports and may potentiate anticoagulant medications such as warfarin by inhibiting CYP450 enzymes including CYP3A4. Icariside II should be avoided during pregnancy and breastfeeding due to a complete lack of safety data and theoretical hormonal activity given its phytoestrogenic structural properties. Individuals on antihypertensive or hormone-sensitive medications should consult a physician before use.